Dr. DeCamp holds the K. Craig Kent Chair in Strategic Leadership and is Professor of Surgery and Chair of the Division of Cardiothoracic Surgery at the University of Wisconsin School of Medicine and Public Health. His clinical efforts are centered on thoracic oncology, a field dominated by lung and esophageal cancer. Additionally, one third of his clinical practice is devoted to interventions for advanced lung disease including lung transplantation and lung volume reduction surgery (LVRS). As a surgical educator, he serves as the Director for UW’s traditional three-year cardiothoracic residency program. His research revolves around risk assessment and reduction of risk for pulmonary resection as well as identification of biomarkers predictive of outcome following lung resection for cancer. He has been an active participant and leader in the NCI-sponsored cooperative oncology process and served on the steering committee of the NHLBI/CMS-sponsored National Emphysema Treatment Trial from 1999 to 2013.
Dr. DeCamp is a Director of the American Board of Thoracic Surgery and a Fellow of both the American College of Surgeons and the American College of Chest Physicians. He is a member of the American Surgical Association, the Society of Thoracic Surgeons, the American Association for Thoracic Surgery and serves on the non-small cell lung cancer, mesothelioma and thymic malignancy panels for the National Comprehensive Cancer Network.
Dr. DeCamp received his medical degree summa
Dr. DeCamp holds the K. Craig Kent Chair in Strategic Leadership and is Professor of Surgery and Chair of the Division of Cardiothoracic Surgery at the University of Wisconsin School of Medicine and Public Health. His clinical efforts are centered on thoracic oncology, a field dominated by lung and esophageal cancer. Additionally, one third of his clinical practice is devoted to interventions for advanced lung disease including lung transplantation and lung volume reduction surgery (LVRS). As a surgical educator, he serves as the Director for UW’s traditional three-year cardiothoracic residency program. His research revolves around risk assessment and reduction of risk for pulmonary resection as well as identification of biomarkers predictive of outcome following lung resection for cancer. He has been an active participant and leader in the NCI-sponsored cooperative oncology process and served on the steering committee of the NHLBI/CMS-sponsored National Emphysema Treatment Trial from 1999 to 2013.
Dr. DeCamp is a Director of the American Board of Thoracic Surgery and a Fellow of both the American College of Surgeons and the American College of Chest Physicians. He is a member of the American Surgical Association, the Society of Thoracic Surgeons, the American Association for Thoracic Surgery and serves on the non-small cell lung cancer, mesothelioma and thymic malignancy panels for the National Comprehensive Cancer Network.
Dr. DeCamp received his medical degree summa